Latest released contribution from Dr. Piazza Fabrizio on Neurology @GreenJournal

What is the accepted risk between optimizing positive effects and reducing ARIA incidence and severity?

Addressing this question might have a profound impact on the design of more effective drugs and clinical trials, not only from a mere safety perspective but, most importantly, in terms of providing a greater understanding of WHY and HOW immunotherapy drugs work?.

http://www.neurology.org/content/88/18/1768/reply#neurology_el;66123

https://www.linkedin.com/pulse/iv-immunoglobulin-alzheimer-disease-aria-win-fabrizio-piazza

https://www.researchgate.net/publication/318273836_IV_immunoglobulin_for_Alzheimer_disease_No_ARIA_no_win